Second Genome is a privately-held biopharmaceutical company. Second Genome's mission is to transform lives with medicines developed through innovative microbiome science.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/20/16 | $42,600,000 | Series B |
Advanced Technology Ventures Adveq Digitalis Ventures Lifeforce Ventures Matthew Winkler Mayo Clinic Ventures MBL Venture Capital Morgenthaler Pfizer Strategic Investments Group Seraph Group | undisclosed |
